Vectura says FDA gives IND approval for VR647

Vectura Group said it has received an Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to conduct a Phase 1 clinical trial with VR647.

VR647 is a drug/device combination, using the AKITA JET smart nebuliser, for the delivery of nebulised budesonide for maintenance treatment and prophylactic therapy of asthma in children (12 months to 8 years) for the US market.

Story provided by